Last reviewed · How we verify

Padcev — Competitive Intelligence Brief

Padcev (AGS-22M6E) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

marketed Nectin-4 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Padcev (AGS-22M6E) — Astellas Pharma. Padcev works by binding to Nectin-4 on the surface of cancer cells, marking them for destruction.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Padcev TARGET AGS-22M6E Astellas Pharma marketed Nectin-4 2019-01-01
ENFORTUMAB VEDOTIN ENFORTUMAB VEDOTIN marketed Nectin-4 2019-01-01
Padcev Ejfv enfortumab-vedotin Astellas Pharma marketed Nectin-4 2019-01-01
Enfortumab padcev Astellas Pharma marketed Nectin-4 2019-01-01
enfortumab vedotin (EV) enfortumab vedotin (EV) Astellas Pharma Global Development, Inc. phase 3 Monoclonal antibody-drug conjugate Nectin-4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Padcev — Competitive Intelligence Brief. https://druglandscape.com/ci/ags-22m6e. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: